Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01637272 · ClinicalTrials.gov registry record · Phase 2
Phase II Study Evaluating Efficacy, Safety and Pharmacokinetics of Pasireotide in Patients With Dumping Syndrome
A Phase 2 study of Dumping Syndrome, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 43
- Enrollment target
- 17
- Study locations
NCT01637272: Completed Phase 2 study of Dumping Syndrome, sponsored by Novartis Pharmaceuticals.
NCT01637272 is a Phase 2 study of Dumping Syndrome that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 43 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (68% lower). The trial reports 17 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01637272, a Phase 2 study of Dumping Syndrome, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 43 participants
- Enrollment target
- 17
- Study locations
Study Summary
multi-center, phase II study evaluating efficacy, safety and pharmacokinetics of pasireotide in patients with dumping syndrome
Primary Outcome
Response rate is defined as percentage of patients with no glucose values \< 60 mg/dL at 90,120, 150 and 180 min during the Oral Glucose Tolerance Test (OGTT) at the end of s.c. dose escalation phase
Conditions Studied
Interventions
- DRUG SOM230
Study Locations (17)
Other
- Novartis Investigative Site - Brussels
- Novartis Investigative Site - Ghent
- Novartis Investigative Site - Leuven
- Novartis Investigative Site - Paris
- Novartis Investigative Site - Pessac
- Novartis Investigative Site - Pierre-Bénite
- Novartis Investigative Site - Hamburg
- Novartis Investigative Site - Würzburg
- Novartis Investigative Site - Groningen
California
- Ximed Center for Weight Management Ximed Research - La Jolla
- Stanford University Medical Center SC - SOM230X2203 - Stanford
Minnesota
- Mayo Clinic - Rochester Mayo MN - Rochester
New York
- Montefiore Medical Center CLCZ696B2320 - The Bronx
Texas
- Texas Tech University Health Science Center - El Paso
Virginia
- Virginia Endocrinology Research SC - Chesapeake
Belgium
- Novartis Investigative Site - Bruges
Netherlands
- Novartis Investigative Site - Utrecht
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 43 participants |
| Start Date | 2013-01-08 |
| Est. Completion | 2015-08-07 |
| Phase | Phase 2 |
What the finished NCT01637272 record still lists
NCT01637272 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 43 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (68% lower).
The record links to 1 condition, with Dumping Syndrome appearing as the primary indexed condition, and to 1 intervention - of which SOM230 is the first listed.
NCT01637272 lists 17 locations in 8 states (Other, California, Minnesota).
Frequently Asked Questions
What is clinical trial NCT01637272 about?
NCT01637272 is a clinical study titled "Phase II Study Evaluating Efficacy, Safety and Pharmacokinetics of Pasireotide in Patients With Dumping Syndrome". multi-center, phase II study evaluating efficacy, safety and pharmacokinetics of pasireotide in patients with dumping syndrome
What is the current status of trial NCT01637272?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 43 participants. The study started on 2013-01-08. Estimated completion is 2015-08-07.
What conditions does trial NCT01637272 study?
This clinical trial studies the following conditions: Dumping Syndrome.
What interventions are being tested in trial NCT01637272?
The interventions under investigation include: SOM230 (DRUG).
Who is sponsoring clinical trial NCT01637272?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01637272 being conducted?
This trial has 17 study locations across California, Minnesota, New York, Texas, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01637272's enrollment target sits among peer trials
43 1332nd of 2000 higher than 662 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03726359 · 43 participants · Phase 1
Phase I Study of Fractionated Stereotactic Radiation Therapy
- NCT03850418 · 43 participants · Phase 2
Azacitidine and Chimerism in MDS or AML Patients After Allogeneic Stem Cell Transplant
- NCT04144023 · 43 participants · Phase 1
A Vaccine (H2NVAC) Before Surgery for the Treatment of HER2-Expressing Ductal Carcinoma In Situ
- NCT04176718 · 43 participants · Phase 2
Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MM
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI